Want to join the conversation?
$PX said that its FY15 sales were $10.8Bil, down 12% vs.2014 due to the impacts of negative FX and lower cost pass-through. Sales were comparable to the prior year as growth from positive price, new project start-ups and acquisitions was offset by lower base volumes in Brazil and China, in the US metals, upstream energy & manufacturing end-markets.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.